Covid ACTIV3 task order supports niaid's goal to better understand the coronavirus with an initial focus on ACTIV3. This task order will initiate the management , oversight , and conduct of the…

Ended Awarded Last action

Contract number
75N91020F00014
Awardee
Awarding agency
Obligated
$9,492,218

Award facts

Contract value 100% obligated
$9,492,217.66 Current and potential, with all options
Completion date 100% complete
  • Current, with exercised options
  • Potential, with all options
Funding agency
National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
Set-aside
No set-aside
Competition
Full and Open Competition Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Frederick, MD 21702, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00012 -$40,507,782
Terminate for Convenience P00011 · EOI:: implementing the presidents department of government efficiency cost efficiency initiative (march 19, 2025)::EOI $0
Other Administrative Action P00010 $0
Other Administrative Action P00009 $0
Other Administrative Action P00008 $0
Other Administrative Action P00007 $0
Other Administrative Action P00006 $0
Other Administrative Action P00005 $0
Other Administrative Action P00004 $0
Other Administrative Action P00003 $0
Other Administrative Action P00002 $0
Other Administrative Action P00001 $0
Original award $50,000,000
Show all 13

About this award

The National Institute of Allergy and Infectious Diseases issued a delivery order to Leidos Biomedical Research Inc. on June 30, 2020, with a ceiling value of $9,492,217.66 under the NIAID master indefinite delivery contract HHSN261201500003I to support clinical trial management, oversight, and conduct for ACTIV3, a multicenter study focused on understanding coronavirus treatment and prevention.

Place of performance is Frederick, Maryland. The order is priced on a cost-plus-fixed-fee basis with an ultimate completion date of August 21, 2026.

Service Contract Inventory reporting captures actual government-invoiced activity across fiscal years 2020 through 2025. FY2020 invoiced $2.6 million; FY2021 recorded 25 contractor hours with zero FTEs; FY2022 invoiced $2.6 million across 110 contractor hours (0.1 FTEs); FY2023 invoiced $820 thousand across 1,395 contractor hours (0.7 FTEs); FY2024 invoiced $3.5 million across 509 contractor hours (0.2 FTEs); and FY2025 invoiced $2.2 million across 2,191 contractor hours (1.1 FTEs). Derived government-paid hourly rates ranged from $587.80/hr (FY2023) to $23,703.38/hr (FY2022), with FY2025 at $987.92/hr. In FY2025, one subcontractor performed 78 percent of contractor hours.

Description

Covid ACTIV3 task order supports niaid's goal to better understand the coronavirus with an initial focus on ACTIV3. This task order will initiate the management , oversight , and conduct of the niaid DCR clinical trial titled a multicenter, ADA

Quick answers

Who was awarded contract 75N91020F00014?

75N91020F00014 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on June 30, 2020.

How much is contract 75N91020F00014 worth?

The government has obligated $9,492,218 on 75N91020F00014.

Which agency awarded contract 75N91020F00014?

National Cancer Institute (National Institutes of Health) awarded 75N91020F00014, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).

Is contract 75N91020F00014 an order under another contract?

Yes. 75N91020F00014 is a delivery order under 75N91019D00024, an indefinite delivery contract.

Was contract 75N91020F00014 competed?

The extent of competition for 75N91020F00014 was full and open competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award